Trials / Completed
CompletedNCT00694083
Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)
A Phase I Study of MK-8669 in Patients With Metastatic or Locally Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
A clinical study evaluates the safety, tolerability, and pharmacokinetics of ridaforolimus (MK-8669) in participants with locally advanced or metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ridaforolimus | Ridaforolimus (MK-8669), 20 or 40 mg administered orally on Day 1 followed by a washout of at least 6 days, then QD x5 (five consecutive days) followed by a 2-day holiday through Day 28 (Cycle 1), and QD x5 followed by a 2-day holiday for 21 days (Cycle 2 and subsequent cycles) |
Timeline
- Start date
- 2008-06-10
- Primary completion
- 2009-09-06
- Completion
- 2009-09-06
- First posted
- 2008-06-10
- Last updated
- 2024-05-21
Source: ClinicalTrials.gov record NCT00694083. Inclusion in this directory is not an endorsement.